Pages that link to "Q43864142"
Jump to navigation
Jump to search
The following pages link to Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia (Q43864142):
Displaying 50 items.
- Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment (Q24814874) (← links)
- Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy (Q25257691) (← links)
- Maraviroc: the evidence for its potential in the management of HIV (Q28476655) (← links)
- Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy (Q28487475) (← links)
- Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes (Q28539169) (← links)
- Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times (Q30655744) (← links)
- Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings (Q33574798) (← links)
- Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database (Q33779622) (← links)
- Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa (Q34625910) (← links)
- Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children (Q34803017) (← links)
- In Vivo Validation of a Bioinformatics Based Tool to Identify Reduced Replication Capacity in HIV-1 (Q34991044) (← links)
- Supervised interruptions of antiretroviral therapy (Q35108735) (← links)
- High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. (Q35156558) (← links)
- Treatment of antiretroviral-drug-resistant HIV-1 infection (Q35610798) (← links)
- Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure (Q35698801) (← links)
- Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy (Q35841783) (← links)
- Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings (Q35905907) (← links)
- Management of HIV-infected patients with multidrug-resistant virus (Q36223772) (← links)
- Effect of injectable contraceptive use on response to antiretroviral therapy among women in Rakai, Uganda (Q36253176) (← links)
- Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the Internati (Q36304546) (← links)
- Drug-resistant virus has reduced ability to induce immune activation (Q36401881) (← links)
- Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy (Q36428713) (← links)
- Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection (Q36464609) (← links)
- The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis (Q36567107) (← links)
- History-adjusted marginal structural models for estimating time-varying effect modification (Q36924003) (← links)
- Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification (Q37003795) (← links)
- Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? (Q37111627) (← links)
- Immune activation and collateral damage in AIDS pathogenesis. (Q37199493) (← links)
- Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD) (Q37364321) (← links)
- Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen (Q37504245) (← links)
- Optimal Allocation of Gold Standard Testing under Constrained Availability: Application to Assessment of HIV Treatment Failure (Q37658177) (← links)
- Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. (Q37823558) (← links)
- Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. (Q37973439) (← links)
- Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy (Q38324341) (← links)
- Factors associated with a strictly undetectable viral load in HIV-1-infected patients (Q39219128) (← links)
- Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch. (Q39528150) (← links)
- Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults (Q39685276) (← links)
- Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy (Q39748924) (← links)
- Immunologic profiles distinguish aviremic HIV-infected adults (Q40800858) (← links)
- Factors associated with long-term CD4 cell recovery in HIV-infected patients on successful antiretroviral therapy (Q40837235) (← links)
- Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada (Q42213902) (← links)
- Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK (Q42772430) (← links)
- US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial (Q42772433) (← links)
- Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK (Q42772436) (← links)
- Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA (Q42772440) (← links)
- A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. (Q43027648) (← links)
- Clinical audit: virological and immunological response to combination antiretroviral therapy in HIV patients at a Sydney sexual health clinic (Q43421983) (← links)
- Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure (Q44113439) (← links)
- A model for reduced HIV-1 viral load monitoring in resource-limited settings (Q44265409) (← links)
- Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment (Q44446088) (← links)